Heterogeneity in prostate cancer: Prostate specific antigen (PSA) and DNA cytophotometry

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1783-1785

  Krause, Frens Steffen ^a,b   Feil, Gerhard ^b   Bichler, Karl Horst ^b   Schrott, Karl M ^a   Akcetin, Ziya Y ^a   Engehausen, Dirk G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

DNA cytophotometry; Prostate cancer; PSA

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

ANEUPLOIDY; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPHOTOMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIPLOIDY; DNA DETERMINATION; EVALUATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; MALE; NEEDLE BIOPSY; PLOIDY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

CYTOPHOTOMETRY; DNA, NEOPLASM; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 21244490049     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. Cancer J Clin 48: 6-29, 1998.
2. Bichler K-H, Feil G, Krause FS, Neide HJ, Mittermueller B and Mattauch W: Die Bedeutung der statischen DNA-Zytometrie in der Diagnostik und Therapie von Prostata- und Harnblasenkarzinom. Fortschritt und Fortbildung in der Medizin 21: Bundesaerztekammer (ed.), Deutscher Aerzte-Verlag, 1997.
3. Boecking A, Chatelin R, Orthen U, Gien G, von Kalkreuth G, Jocham D and Wohltmann D: DNA-grading of prostatic carcinoma: Prognostic validity and reproducibility. Anticancer Res 8: 129-136, 1988.
4. Boecking A: DNA-Zytometrie und Automation in der klinischen. Diagnostik Beitr Onkol 38: 298-347, 1990.
5. Tavares AS, Costa J, De Carvalho A and Reis M: Tumor ploidy and prognosis in carcinomas of the bladder and prostate. Br J Cancer 20: 438-441, 1966.
6. Tavares AS, Costa J and Costa M: Correlation between ploidy and prognosis in prostatic carcinoma. J Urol 109: 676-679, 1973.
7. Cremer TH, Jauch A, Ried TH, Schöck E, Lengauer CH, Cremer M and Speicher MR: Fluoreszenz-in-situ-Hybridisierung. Dt. Aerzteblatt 22: 1177-1185, 1995.
8. Fu YS, Cheng L, Huang I, Huang S, Wiesmeier E, Wettstein F and Weissman M: DNA ploidy analysis of cervical condyloma and intraepithelial neoplasia in specimens obtained by punch biopsy. Anal Quant Cytol Histol 77: 187-195, 1989.
9. Mora LB, Moscinski LC, Diaz JI, Blair P, Cantor AB and Pow-Sang JM: Stage B prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control 6: 587-591, 1999.
10. Badalament RA, O'Toole RV, Young DC and Drago JR: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67: 3014-23, 1991.
11. Jones EC, McNeal J, Bruchowsky N and de Jong G: DNA content in prostatic adenocarcinoma. A flow cytometric study of the predictive value of aneuploidy for tumor volume, percentage Gleason Grade 4 and 5, and lymph node metastases. Cancer 66: 752-757, 1990.